


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+14.13%
-16.25%
+2.42%
-2.51%
FULC
Fulcrum Therapeutics
$8.34
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
FULC Price Performance
$10.73 (-22.27%)
$8.95 (-6.82%)
$9.5 (-12.21%)
$3.12 (+167.31%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
FULC Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
FULC Street Sentiment is extremely bullish and have positive views on the near-term outlook
FULC has Low risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Jan 13, 2026
Initiate
Overweight
JP Morgan
Dec 12, 2025
Reiterate
Buy
Truist Securities
SNY
Sanofi
48.47
+0.28%
PFE
Pfizer
27.58
+1.71%
NVO
Novo Nordisk A/S
37.42
-0.51%
What is FULC current stock price?
What are FULC stock strengths?
What is FULC Risk Level?
What is FULC market cap and volume?
What is FULC current Stock IQ?
Should I buy FULC stock right now?
Is FULC a Strong Buy right now?
What does a 'Strong Buy' rating mean for FULC?
What does a 'Strong Sell' rating mean for FULC?
What factors influence FULC's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
FULC
Fulcrum Therapeutics
Current Price
$8.34
Runners Also Watch
SNY
Sanofi
48.47
+0.28%
PFE
Pfizer
27.58
+1.71%
NVO
Novo Nordisk A/S
37.42
-0.51%

FULC Price Performance
$10.73 (-22.27%)
$8.95 (-6.82%)
$9.5 (-12.21%)
$3.12 (+167.31%)
FULC Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
FULC Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
FULC Street Sentiment is extremely bullish and have positive views on the near-term outlook
FULC has Low risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
FULC Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
FULC Latest Analysis
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease. ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12) representing a rapid robust and clinically relevant response with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ―
Tue Feb 24, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025. ― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
Tue Feb 24, 2026
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?. The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Thu Feb 12, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
FULC Stock trends
FULC Stock performance
FULC Stock analysis
FULC investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.